A benzoxazole compound as a novel MEK inhibitor for the treatment of RAS/RAF mutant cancer-Reference-Cited by-同舟云学术

A benzoxazole compound as a novel MEK inhibitor for the treatment of RAS/RAF mutant cancer

Published:2019-01-28 Issue:2 Volume:145 Page:586-596
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Cheng Ying¹²,Wang Xingkai³,Xia Xiangying³,Zhang Wei²,Tian Hongqi¹^ORCID

Affiliation:

1. Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation MedicineChinese Academy of Medical Sciences and Peking Union Medical College Tianjin China

2. Center for Marine Bioproducts Development, College of Medicine and Public HealthFlinders University Adelaide SA Australia

3. Binjiang Pharma, Inc. Tianjin China

Funder

CAMS Innovation Fund for Medical Science from the Chinese Academy of Medical Sciences & Peking Union Medical College

Fundamental Research Fund for CAMS & PUMC

Innovation Team Funding from the Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.32119

Reference37 articles.

1. MEK inhibition in non-small cell lung cancer

2. Molecular Pathways: The Basis for Rational Combination Using MEK Inhibitors in KRAS-Mutant Cancers

3. Characterization of a Novel Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor with a Unique Mechanism of Action for Cancer Therapy

4. MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors

5. RAS oncogene activation induces proliferation in normal human thyroid epithelial cells without loss of differentiation

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Direct Arylation of Benzoxazoles with Benzoyl Chlorides under Mild Conditions;European Journal of Organic Chemistry;2024-06-27

2. Targeting disease with benzoxazoles: a comprehensive review of recent developments;Medicinal Chemistry Research;2024-02-18

3. Navigating the ERK1/2 MAPK Cascade;Biomolecules;2023-10-20

4. Evaluation of the radiosensitizing effect of MEK inhibitor KZ-001 on non-small cell lung cancer cells in vitro;Asian Biomedicine;2023-10-01

5. Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor;Frontiers in Pharmacology;2023-09-21